JP2010523682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523682A5 JP2010523682A5 JP2010503086A JP2010503086A JP2010523682A5 JP 2010523682 A5 JP2010523682 A5 JP 2010523682A5 JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010523682 A5 JP2010523682 A5 JP 2010523682A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- alkoxy
- halogen
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 21
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical group 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 12
- 125000002757 morpholinyl group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- -1 amino, morpholinyl Chemical group 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000000466 oxiranyl group Chemical group 0.000 claims 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 3
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000001474 proteinuria Diseases 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 230000003205 diastolic effect Effects 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 claims 1
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 102000012936 Angiostatins Human genes 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000011057 Breast sarcoma Diseases 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229940087620 aromasin Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 claims 1
- 229950010152 halofuginone Drugs 0.000 claims 1
- 229950000038 interferon alfa Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 229960002633 ramucirumab Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229950001248 squalamine Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91161207P | 2007-04-13 | 2007-04-13 | |
| PCT/US2008/004809 WO2008127714A1 (en) | 2007-04-13 | 2008-04-12 | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523682A JP2010523682A (ja) | 2010-07-15 |
| JP2010523682A5 true JP2010523682A5 (cg-RX-API-DMAC7.html) | 2011-10-20 |
Family
ID=39618825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503086A Pending JP2010523682A (ja) | 2007-04-13 | 2008-04-12 | 癌及び他の疾患の治療に有用なカルボリン誘導体の投与 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100158858A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2139476A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010523682A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008239598A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2683444A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008127714A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076353B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US7601840B2 (en) * | 2004-03-15 | 2009-10-13 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
| WO2009061448A2 (en) * | 2007-11-08 | 2009-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| WO2010138659A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| WO2010138652A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating kaposi sarcoma |
| WO2010138758A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| WO2010138706A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
| US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
| US20120157401A1 (en) * | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| EP2435437A4 (en) | 2009-05-27 | 2012-10-31 | Ptc Therapeutics Inc | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES |
| AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| PT3004090T (pt) | 2013-05-28 | 2017-12-22 | Astrazeneca Ab | Compostos químicos |
| US10307406B2 (en) | 2013-08-31 | 2019-06-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor |
| CA2952897A1 (en) | 2014-06-27 | 2015-12-30 | Nogra Pharma Limited | Aryl receptor modulators and methods of making and using the same |
| RS60824B1 (sr) | 2014-12-18 | 2020-10-30 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indoli kao modulatori estrogenih receptora i njihova upotreba |
| JP2019001715A (ja) * | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | 三環性化合物 |
| KR20220071293A (ko) | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| EP3554494A4 (en) | 2016-12-19 | 2021-02-17 | Cellixbio Private Limited | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION |
| EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
| US10519152B2 (en) * | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| PL3810283T3 (pl) | 2018-06-21 | 2023-10-16 | F. Hoffmann-La Roche Ag | Postacie stałe soli winianowej 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropylo)azetydyn-3-ylo)amino)fenylo)-3-metylo-1,3,4,9-tetrahydro-2H-pirydo[3,4-b]indol-2-ilo)-2,2-difluoropropan-1-olu, sposób ich otrzymywania i sposoby ich zastosowania w leczeniu nowotworów |
| US20210205225A1 (en) | 2018-08-03 | 2021-07-08 | Ptc Therapeutics, Inc. | Bioavailable oral dosage forms |
| AU2019340402B2 (en) | 2018-08-17 | 2025-04-03 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| CA3126163A1 (en) | 2019-01-15 | 2020-07-23 | Ptc Therapeutics, Inc. | Method for treating an acute myeloid leukemia |
| KR20220044528A (ko) | 2019-08-06 | 2022-04-08 | 리커리엄 아이피 홀딩스, 엘엘씨 | 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제 |
| US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US282849A (en) * | 1883-08-07 | Fruit-jar | ||
| US272759A (en) * | 1883-02-20 | Desk-top | ||
| US254878A (en) * | 1882-03-14 | Train-boat | ||
| US40527A (en) * | 1863-11-03 | Improvement in cooking-stoves | ||
| US64683A (en) * | 1867-05-14 | mason and joseph messinger | ||
| AU2001283964A1 (en) * | 2000-08-09 | 2002-02-18 | Pharmacia And Upjohn Company | Composition for combined use of aromatase inhibitors |
| AU2002249890A1 (en) * | 2001-02-12 | 2002-08-28 | Lilly Icos Llc | Carboline derivatives |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
-
2008
- 2008-04-12 WO PCT/US2008/004809 patent/WO2008127714A1/en not_active Ceased
- 2008-04-12 EP EP08742866A patent/EP2139476A1/en not_active Withdrawn
- 2008-04-12 JP JP2010503086A patent/JP2010523682A/ja active Pending
- 2008-04-12 CA CA002683444A patent/CA2683444A1/en not_active Abandoned
- 2008-04-12 US US12/595,134 patent/US20100158858A1/en not_active Abandoned
- 2008-04-12 AU AU2008239598A patent/AU2008239598A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523682A5 (cg-RX-API-DMAC7.html) | ||
| RU2497526C2 (ru) | Производные бензилбензола и способы их применения | |
| AU2012258575B2 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| JP2010530376A5 (cg-RX-API-DMAC7.html) | ||
| WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
| RU2012123372A (ru) | Гетероциклические модуляторы транспортеров атф-связывающей кассеты | |
| RU2018133158A (ru) | Способы применения агонистов fxr | |
| RU2469042C2 (ru) | Терапевтически активные триазолы и их использование | |
| JP2016538313A5 (cg-RX-API-DMAC7.html) | ||
| JP2011529054A5 (cg-RX-API-DMAC7.html) | ||
| UA96302C2 (en) | Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid | |
| JP2011502958A5 (cg-RX-API-DMAC7.html) | ||
| HRP20120696T1 (hr) | Spiro-prstenasti spoj i njegova medicinska upotreba | |
| RU2012117786A (ru) | Новое производное фенола | |
| JP2013531070A5 (cg-RX-API-DMAC7.html) | ||
| UA88104C2 (ru) | Производные пиридазинона как агонисты рецептора тиреоидного гормона | |
| JP2010077141A5 (cg-RX-API-DMAC7.html) | ||
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2009507896A5 (cg-RX-API-DMAC7.html) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JO2784B1 (en) | 5,3,1 - Triazole substitute derivative | |
| JP2012530765A5 (cg-RX-API-DMAC7.html) | ||
| AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos |